Aldesleukin

Also known as: T-cell growth factor (TCGF) Interleukin-2 precursor IL-2

Therapeutic indications

Aldesleukin is indicated for:

Metastatic renal cell carcinoma (metastatic RCC)

Population group: both men and women, only adults (18 years old or older)

Aldesleukin is indicated for the treatment of metastatic renal cell carcinoma.

Risk factors associated with decreased response rates and median survival are:

  • A performance status of ECOG* 1 or greater
  • More than one organ with metastatic disease sites
  • A period of <24 months between initial diagnosis of primary tumour and the date the patient is evaluated for aldesleukin treatment.

* ECOG (Eastern Cooperative Oncology Group) 0 = normal activity, 1 = symptoms but ambulatory; 2 = in bed less than 50% of time; 3 = in bed more than 50% of time.

Response rates and median survival decrease with the number of risk factors present. Patients positive for all three risk factors should not be treated with aldesleukin.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Aldesleukin is contraindicated in the following cases:

Patients with a performance status of ECOG ≥2

at least one of
ECOG performance status - grade 2
ECOG performance status - grade 3
ECOG performance status - grade 4
ECOG performance status - grade 5

Severe cardiac disease

at least one of
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV

Active infection

Hypoxia PaO2 <60 mmHg during rest

Hypoxia

Severe major organ dysfunction

Single organ dysfunction

Central Nervous System metastases or seizure disorders

at least one of
CNS metastases
Epilepsy
Status epilepticus

Organ allografts

Allograft

Corticosteroids

Corticosteroid drugs

Auto-immune disease

Autoimmune disease

Severe lethargy or somnolence

at least one of
Stupor
Disorder of excessive somnolence

Interferon-alpha

at least one of
Interferon, alfa-2a
Interferon, alfa-2b

Cis-platinum, vinblastine, dacarbazine

at least one of
Cis-Diaminedichloroplatinum
Vinblastine
Dacarbazine

Contrast media

Contrast media

Pregnancy

Pregnancy

Lactation

Lactation

Effects on ability to drive and use machines

Effects on ability to drive and use machines

Serum creatinine borderline high

Serum creatinine raised

Serum bilirubin borderline high

Serum bilirubin borderline high

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: PROLEUKIN Powder for solution for injection or infusion
< Previous: Overview
Next: Precautions >